Download PDF
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2010; 31(04): 103-104
DOI: 10.4103/0971-5851.76189
EDITORIAL

Progression-free or overall... That is the question...

Authors

  • Sudeep Gupta

    Editor-in-Chief, Associate Professor of Medical Oncology,Tata Memorial Hospital, India
Further Information
Also available at
 PDF Download Permissions and Reprints
Preview Container


Publication History

Article published online:
16 August 2021

© 2010. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Safety, MedWatch. Avastin (bevacizumab): Process for Removal of Breast Cancer Indication Begun. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237280.htm [last accessed on 2011 Jan 16].
  • 2 Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
  • 3 Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
  • 4 Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatovet O, et al. RIBBON-1: Randomized double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Program and abstracts of the 2009 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2009; Orlando, Florida. Abstract 1005.
  • 5 O′Shaughnessy J, Miles D, Gray R, Dieras V, Perez EA, Zon R, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). Program and abstracts of the 2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois. Abstract 1005.